290 related articles for article (PubMed ID: 1404819)
1. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
Farlow M; Gracon SI; Hershey LA; Lewis KW; Sadowsky CH; Dolan-Ureno J
JAMA; 1992 Nov; 268(18):2523-9. PubMed ID: 1404819
[TBL] [Abstract][Full Text] [Related]
2. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
4. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Zemlan FP
J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled study of tacrine in Chinese patients with Alzheimer's disease.
Wong WJ; Liu HC; Fuh JL; Wang SJ; Hsu LC; Wang PN; Sheng WY
Dement Geriatr Cogn Disord; 1999; 10(4):289-94. PubMed ID: 10364647
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
7. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
Clipp EC; Moore MJ
Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E genotype and gender influence response to tacrine therapy.
Farlow MR; Lahiri DK; Poirier J; Davignon J; Hui S
Ann N Y Acad Sci; 1996 Dec; 802():101-10. PubMed ID: 8993489
[TBL] [Abstract][Full Text] [Related]
9. The cardinal features of cognitive and noncognitive dysfunction and the differential efficacy of tacrine in Alzheimer's disease patients.
Talwalker S
J Biopharm Stat; 1996 Nov; 6(4):443-56. PubMed ID: 8969979
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer's disease.
Forette F; Hoover T; Gracon S; de Rotrou J; Hervy MP; Lechevalier B; Micas M; Petit H; Orgogozo JM; Guard O; Saudeau D; Forette B; Michel B; Emile J; Augustin P; Wang A; Vignat J; Allain H; Cuny G; Leger JM; Collard M; Joyeux O; Khalil R
Eur J Neurol; 1995 Jul; 2(3):229-38. PubMed ID: 24283645
[TBL] [Abstract][Full Text] [Related]
11. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group.
Le Bars PL; Katz MM; Berman N; Itil TM; Freedman AM; Schatzberg AF
JAMA; 1997 Oct 22-29; 278(16):1327-32. PubMed ID: 9343463
[TBL] [Abstract][Full Text] [Related]
12. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.
Watkins PB; Zimmerman HJ; Knapp MJ; Gracon SI; Lewis KW
JAMA; 1994 Apr; 271(13):992-8. PubMed ID: 8139084
[TBL] [Abstract][Full Text] [Related]
13. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.
Raskind MA; Sadowsky CH; Sigmund WR; Beitler PJ; Auster SB
Arch Neurol; 1997 Jul; 54(7):836-40. PubMed ID: 9236571
[TBL] [Abstract][Full Text] [Related]
14. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
Qizilbash N; Whitehead A; Higgins J; Wilcock G; Schneider L; Farlow M
JAMA; 1998 Nov; 280(20):1777-82. PubMed ID: 9842955
[TBL] [Abstract][Full Text] [Related]
15. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
Chatellier G; Lacomblez L
BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
[TBL] [Abstract][Full Text] [Related]
16. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
van Dyck CH; Newhouse P; Falk WE; Mattes JA
Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618
[TBL] [Abstract][Full Text] [Related]
17. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
Schneider LS; Farlow MR; Henderson VW; Pogoda JM
Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
[TBL] [Abstract][Full Text] [Related]
18. Tacrine: first drug approved for Alzheimer's disease.
Crismon ML
Ann Pharmacother; 1994 Jun; 28(6):744-51. PubMed ID: 7919566
[TBL] [Abstract][Full Text] [Related]
19. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
20. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
